• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    8/9/23 1:31:06 PM ET
    $BLFS
    $BNTC
    $DBTX
    $INFI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLFS alert in real time by email

    Gainers

    • Tango Therapeutics (NASDAQ:TNGX) stock moved upwards by 90.3% to $7.29 during Wednesday's regular session. Trading volume for Tango Therapeutics's stock is 56.0 million as of 13:30 EST. This is 26711.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $644.9 million. As per the press release, Q2 earnings came out 2 days ago.
    • Benitec Biopharma (NASDAQ:BNTC) shares rose 76.16% to $3.4. As of 13:30 EST, this security is trading at a volume of 22.2 million shares, making up 7273.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.5 million.
    • Decibel Therapeutics (NASDAQ:DBTX) stock moved upwards by 75.98% to $4.91. Trading volume for this security as of 13:30 EST is 5.0 million, which is 17771.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $122.8 million.
    • Renovaro Biosciences (NASDAQ:RENB) stock increased by 68.23% to $1.43. Trading volume for this security as of 13:30 EST is 30.7 million, which is 3172.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $91.0 million.
    • Science 37 Hldgs (NASDAQ:SNCE) shares increased by 43.09% to $0.39. The current volume of 20.5 million shares is 4652.2% of Science 37 Hldgs's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $45.1 million. The company's, Q2 earnings came out yesterday.
    • Poseida Therapeutics (NASDAQ:PSTX) shares rose 33.58% to $2.65. As of 13:30 EST, this security is trading at a volume of 3.0 million shares, making up 290.5% of its average full-day volume over the last 100 days. The company's market cap stands at $251.5 million. As per the press release, Q2 earnings came out yesterday.

    Losers

    • Palisade Bio (NASDAQ:PALI) shares fell 64.4% to $0.69 during Wednesday's regular session. As of 13:30 EST, Palisade Bio's stock is trading at a volume of 3.6 million, which is 1120.1% of its average full-day volume over the last 100 days. The company's market cap stands at $4.6 million.
    • Mallinckrodt (AMEX:MNK) stock declined by 35.18% to $0.94. The current volume of 2.1 million shares is 45.6% of Mallinckrodt's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $12.3 million.
    • BioLife Solns (NASDAQ:BLFS) shares decreased by 28.2% to $13.21. As of 13:30 EST, BioLife Solns's stock is trading at a volume of 1.5 million, which is 463.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $574.2 million. As per the news, the Q2 earnings report came out yesterday.
    • Seer (NASDAQ:SEER) shares fell 26.94% to $3.4. Trading volume for Seer's stock is 368.0K as of 13:30 EST. This is 147.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $217.0 million. The company's, Q2 earnings came out yesterday.
    • Vivos Therapeutics (NASDAQ:VVOS) shares declined by 24.96% to $0.3. As of 13:30 EST, this security is trading at a volume of 3.2 million shares, making up 229.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.9 million.
    • Infinity Pharmaceuticals (NASDAQ:INFI) shares decreased by 24.51% to $0.1. As of 13:30 EST, this security is trading at a volume of 7.7 million shares, making up 282.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BLFS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLFS
    $BNTC
    $DBTX
    $INFI

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    3/26/2026$7.00Buy
    H.C. Wainwright
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Tango Therapeutics Inc.
    $TNGX
    2/23/2026$19.00Outperform
    Mizuho
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Tango Therapeutics Inc.
    $TNGX
    11/18/2025Peer Perform
    Wolfe Research
    Tango Therapeutics Inc.
    $TNGX
    8/19/2025$11.00Overweight
    Piper Sandler
    BioLife Solutions Inc.
    $BLFS
    7/22/2025$30.00Overweight
    Stephens
    More analyst ratings

    $BLFS
    $BNTC
    $DBTX
    $INFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Palisade Bio with a new price target

    H.C. Wainwright initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    3/26/26 8:49:56 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Tango Therapeutics with a new price target

    Mizuho initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $19.00

    2/23/26 8:40:01 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLFS
    $BNTC
    $DBTX
    $INFI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLFS
    $BNTC
    $DBTX
    $INFI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.

    SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    3/27/26 1:31:59 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by BioLife Solutions Inc.

    SCHEDULE 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

    3/26/26 4:11:27 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by Tango Therapeutics Inc.

    144 - Tango Therapeutics, Inc. (0001819133) (Subject)

    3/25/26 4:24:42 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLFS
    $BNTC
    $DBTX
    $INFI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

    Insurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to Legacy Business Model to Focus on Scaling its Medical Affiliation Distribution Model LITTLETON, Colo., March 26, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (OSA), today announced that physician-owned professional entities supported by t

    3/26/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

    VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science. That capital is not spreading evenly: it is concentrating on precision medicine, where the global oncology precision medicine market is projected to reach $303 billion by 2035[2], growing at approximately 9% annually as targeted cancer treatments move from promising idea to standard care. The five companies in thi

    3/19/26 11:00:00 AM ET
    $ATOS
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

    LITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health conditions, today announced that an a recent study published in the Journal of Clinical Medicine supports Vivos' long maintained belief that dental and facial morphology characterized by narrow palatal (upper) dental arches, high peaked palates, and recessed lower jaws were directly correlated to the prevalence and severity of obstructive sleep apnea (OSA) in adults and children. Over the past decade, Vivos-trained provider

    3/17/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $BLFS
    $BNTC
    $DBTX
    $INFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Crystal Adam

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    3/27/26 8:06:56 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by De Greef Roderick

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    3/23/26 5:09:09 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Berard Todd

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    3/23/26 5:09:03 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    $BNTC
    $DBTX
    $INFI
    Leadership Updates

    Live Leadership Updates

    View All

    Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n

    3/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLFS
    $BNTC
    $DBTX
    $INFI
    Financials

    Live finance-specific insights

    View All

    Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan ("NOL Plan") designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets ("NOLs"). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subject to any expiration date, represent a valuable asset of Seer and are available to reduce Seer's future federal income tax expense. The NOL Plan is similar to those adopted by numerous o

    2/26/26 4:06:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insigh

    2/26/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

    Fourth quarter 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-yearGAAP gross margin of 63% and non-GAAP adjusted gross margin of 64% for the fourth quarterGAAP net income of $2.1 million or $0.04 per share and adjusted EBITDA of $6.9 million, or 28% of total revenue for the fourth quarterExpects 2026 revenue growth of $112.5 million to $115.0 million, up 17%-20% over 2025Conference call begins at 4:30 p.m. Eastern time todayBOTHELL, Wash., Feb. 26, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and serv

    2/26/26 4:03:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    $BNTC
    $DBTX
    $INFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Tango Therapeutics Inc.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/20/24 4:24:26 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care